PuSH - Publication Server of Helmholtz Zentrum München: Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Schuster, F.R.* ; Stanglmaier, M.* ; Woessmann, W.* ; Winkler, B.* ; Siepermann, M.* ; Meisel, R.* ; Schlegel, P.G.* ; Hess J.* ; Lindhofer, H.G.* ; Borkhardt, A.* ; Buhmann, R.

Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.

Br. J. Haematol. 169, 90-102 (2015)

DOI

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

Summary: Children with B cell malignancies refractory to standard therapy are known to have a poor prognosis and very limited treatment options. Here, we report on the treatment and follow-up of ten patients diagnosed with relapsed or refractory mature B-cell Non Hodgkin Lymphoma (B-NHL), Burkitt leukaemia (B-AL) or pre B-acute lymphoblastic leukaemia (pre B-ALL). All children were treated with FBTA05 (now designated Lymphomun), an anti-CD3 x anti-CD20 trifunctional bispecific antibody (trAb) in compassionate use. Within individual treatment schedules, Lymphomun was applied (a) after allogeneic stem cell transplantation (allo-SCT, n = 6) to induce sustained long-term remission, or (b) stand alone prior to subsequent chemotherapy to eradicate residual disease before allo-SCT (n = 4). Nine of ten children displayed a clinical response: three stable diseases (SD), one partial remission (PR) and five induced or sustained complete remissions (CR). Five of these nine responders died during follow-up. The other patients still maintain CR with a current overall survival of 874-1424 days (median: 1150 days). In conclusion, despite the dismal clinical prognosis of children refractory to standard therapy, immunotherapy with Lymphomun resulted in a favourable clinical outcome in this cohort of refractory paediatric patients.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Anti-cd20 X Anti-cd3 ; B-cell Malignancies ; Bispecific Antibody ; Children ; Immunotherapy; Non-hodgkin-lymphoma; Acute-lymphoblastic-leukemia; Lasting Antitumor Immunity; Central-nervous-system; Bispecific Antibody; Allogeneic Lymphocytes; Accessory Cells; Cancer-therapy; Phase Ii/iii; T-cells

ISSN (print) / ISBN 0007-1048

e-ISSN 1365-2141

Journal British Journal of Haematology

Quellenangaben Volume: 169, Issue: 1, Pages: 90-102

Publisher Wiley

Publishing Place Hoboken

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) CCG Hematopoetic Cell Transplants (IMI-KHZ)